Skip to main content
. 2006 Jul 12;62(4):457–472. doi: 10.1111/j.1365-2125.2006.02690.x

Figure 2.

Figure 2

The incidence of short-term (2-week) side-effects, including myelotoxicity, gastrointestinal (GI) symptoms, and infection with different GSTM1, GSTT1 and GSTP1 genotypes in SLE patients receiving pulsed high-dose (1.0 g) cyclophosphamide (CTX) therapy. The incidence of myelotoxicity and GI symptoms was significantly higher in patients with the GSTP1-*105I/V or GSTP1-105 V/V genotype than in patients with the GSTP1 wildtype genotype (P < 0.001 and P < 0.05, respectively)